FIG 2.

Spider plot of tumor burden changes during the first-line pembrolizumab monotherapy. The spider plot visually presents the tumor burden dynamics in 88 patients treated with the first-line pembrolizumab monotherapy. Fifty-five patients whose tumor burden stayed below the baseline burden (< 1.0 or < 0% increase) had longer survival compared with others who had ≥ 0% increase in tumor burden in the subsequent analyses. One patient demonstrated an initial tumor burden increase meeting the criteria for RECIST progression followed by tumor shrinkage, representing pseudoprogression with subsequent tumor response (black line indicated by a black arrow).